Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) just unveiled an update.
Qiagen reported that the Dutch financial regulator AFM has disclosed a substantial holdings notification concerning BlackRock, Inc.’s position in the company. According to the filing, BlackRock holds a combined capital interest of 10.67% and voting rights of 11.81% in Qiagen through a range of affiliated entities and instruments, including ordinary shares and contracts for difference.
The announcement underscores the presence of a major global asset manager among Qiagen’s largest shareholders, potentially signaling sustained institutional confidence in the company. Qiagen emphasized that it is not responsible for the accuracy of the AFM data, which is sourced directly from the regulator’s public register, but the disclosure nevertheless highlights a significant level of concentrated ownership in its stock.
The most recent analyst rating on (QGEN) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences company listed in Frankfurt and on U.S. and Swiss exchanges. The firm provides molecular diagnostics and sample preparation technologies used in research, clinical testing and pharmaceutical development, serving laboratories and healthcare customers worldwide.
Average Trading Volume: 2,448,739
Technical Sentiment Signal: Sell
Current Market Cap: $8.27B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.